한빛사논문
- 조회347
Jiyeon Oh1,12, Myeongcheol Lee2,3,12, Minji Kim2,3,12, Hyeon Jin Kim2,3,12, Seung Won Lee4, Sang Youl Rhee2,5, Ai Koyanagi6, Lee Smith7, Min Seo Kim8, Hayeon Lee2,9,13, Jinseok Lee9,10,13 & Dong Keon Yon1,2,3,11,13
1Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
2Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.
3Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
4Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, South Korea.
5Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, South Korea.
6Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
7Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
8Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
9Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea.
10Department of Electronics and Information Convergence Engineering, Kyung Hee University, Yongin, South Korea.
11Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, South Korea.
12These authors contributed equally: Jiyeon Oh, Myeongcheol Lee, Minji Kim, Hyeon Jin Kim.
13These authors jointly supervised this work: Hayeon Lee, Jinseok Lee, Dong Keon Yon.
Corresponding authors : Correspondence to Hayeon Lee, Jinseok Lee or Dong Keon Yon.
Abstract
As mounting evidence suggests a higher incidence of adverse consequences, such as disruption of the immune system, among patients with a history of COVID-19, we aimed to investigate post-COVID-19 conditions on a comprehensive set of allergic diseases including asthma, allergic rhinitis, atopic dermatitis, and food allergy. We used nationwide claims-based cohorts in South Korea (K-CoV-N; n = 836,164; main cohort) and Japan (JMDC; n = 2,541,021; replication cohort A) and the UK Biobank cohort (UKB; n = 325,843; replication cohort B) after 1:5 propensity score matching. Among the 836,164 individuals in the main cohort (mean age, 50.25 years [SD, 13.86]; 372,914 [44.6%] women), 147,824 were infected with SARS-CoV-2 during the follow-up period (2020−2021). The risk of developing allergic diseases, beyond the first 30 days of diagnosis of COVID-19, significantly increased (HR, 1.20; 95% CI, 1.13−1.27), notably in asthma (HR, 2.25; 95% CI, 1.80−2.83) and allergic rhinitis (HR, 1.23; 95% CI, 1.15−1.32). This risk gradually decreased over time, but it persisted throughout the follow-up period (≥6 months). In addition, the risk increased with increasing severity of COVID-19. Notably, COVID-19 vaccination of at least two doses had a protective effect against subsequent allergic diseases (HR, 0.81; 95% CI, 0.68−0.96). Similar findings were reported in the replication cohorts A and B. Although the potential for misclassification of pre-existing allergic conditions as incident diseases remains a limitation, ethnic diversity for evidence of incident allergic diseases in post-COVID-19 condition has been validated by utilizing multinational and independent population-based cohorts.
논문정보
- Research article
- 2024년 04월 (BRIC 등록일 2024-04-02)
- 국내 연구진
- 바이오·의료융합 > 다학제 융합/복합
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
